Paxlovid as a potential treatment for long COVID.

Paxlovid as a potential treatment for long COVID.

Publication date: Sep 21, 2023

On 31 July 2023, the United States Department of Health and Human Services announced the formation of the Office of Long COVID Research and Practice and the United States National Institutes of Health opened enrollment for RECOVER-Vital, a randomized study to evaluate new treatment options for long Coronavirus (long COVID). The RECOVER Initiative is a $1. 15 billion research platform intended to describe, categorize, treat, and prevent long-term symptoms following infection by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that causes Coronavirus (COVID-19). More than 200 symptoms have been associated with long COVID, potentially affecting nearly all body systems, and current estimates suggest that between 7 million and 23 million Americans have developed long COVID. However, there are no approved treatments for this condition. The first prospective, randomized study of the RECOVER research initiative, RECOVER-Vital, will evaluate the SARS-CoV-2 antiviral nirmatrelvir/ritonavir (Paxlovid) as a potential treatment for long COVID. This manuscript explores what is known about Paxlovid to treat and prevent long COVID and examines the rationale for addressing this condition with an antiviral agent.

Concepts Keywords
Americans Long COVID
Coronavirus nirmatrelvir
July paxlovid
Pharmacother ritonavir


Type Source Name
disease MESH long COVID
disease MESH infection
disease VO Severe acute respiratory syndrome coronavirus 2
disease MESH causes
disease MESH COVID-19
drug DRUGBANK Ritonavir

Original Article

(Visited 1 times, 1 visits today)